Article | January 1, 2022

Do Not Let HCPs Delay Your Biologics Route To Market

Source: Cytiva
GettyImages-1264101698-lab-research-scientist

The stakes are high in biologics development, especially in host cell protein (HCP) analysis. Get it wrong and it could delay your development cycle. See how optimizing your HCP assays can smooth your route to market.

In this article, review Chinese hamster ovary (CHO) cells, the challenge of analyzing HCPs, analyzing HCPs in biosimilars, and how to determine which HCP ELISA coverage assay to use.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: